Diagnostic value of neutrophil to lymphocyte ratio to rule out chronic obstructive pulmonary disease exacerbation from acute heart failure in the emergency department by Demirtaş, Erdal & Demirtaş, Esin
Disaster and Emergency Medicine Journal 
2019, Vol. 4, No. 3, 102–108
DOI: 10.5603/DEMJ.2019.0021
Copyright © 2019 Via Medica 
ISSN 2451–4691
102 Copyright © 2019 Via Medica, ISSN 2451–4691
original article
Diagnostic value of neutrophil to lymphocyte 
ratio to rule out chronic obstructive 
pulmonary Disease exacerbation from acute 
heart failure in the emergency Department
Erdal Demirtaş1 , Esin Demirtaş2
1Department of Emergency Medicine, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkey
2Department of Family Medicine, Sivas Cumhuriyet University Faculty of Medicine, Sivas, Turkey
ABSTRACT 
INTRODUCTION: This study was performed to determine whether neutrophil-lymphocyte ratio (NLR) optimiz-
es the differential diagnosis of acute chronic obstructive pulmonary disease (COPD) exacerbation and acute 
heart failure (AHF) in patients admitting to the emergency department (ED) with dyspnoea. 
MATERIAL AND METHODS: The study group included 241 patients (135 males and 106 females) who were 
admitted to the ED with a complaint of dyspnoea between January 2016 November 2018 and were hospi-
talized with diagnosis of acute COPD exacerbation or AHF. 
RESULTS: White blood cell count, neutrophil, haemoglobin, haematocrit, NLR, and C-reactive protein values 
in patients with COPD exacerbation were significantly higher compared to those with AHF (p < 0.05). The 
largest areas under the ROC curve were obtained with NLR. The cut-off value for NLR was 9.39, with a sen-
sitivity of 71% and a specificity of 61%. 
CONCLUSIONS: In conclusion, the NLR has diagnostic value to the conventional clinical assessment in patients 
with acute dyspnoea at ED, especially with acute COPD exacerbation requiring inpatient management. This 
may be an additional tool during the differential diagnosis of dyspnoea for emergency physicians in hospitals 
without advanced laboratory facilities. 
KEY WORDS: neutrophil-lymphocyte ratio; dyspnoea; acute COPD exacerbation; acute heart failure;  
emergency medicine
Disaster Emerg Med J 2019; 4(3): 102–108
ADDRESS fOR CORRESpONDENCE:
Dr Erdal Demirtaş, Department of Emergency Medicine, Sivas Cumhuriyet University Faculty of Medicine, TR-58140, Sivas, Turkey 
e-mail: demirtas.erdal@hotmail.com
INTRODUCTION
The diagnosis and management of patients admit-
ting to the emergency departments (ED) with acute 
dyspnoea and accompanying hypoxemia are compli-
cated due to the wide spectrum of differential diag-
nosis. Following stabilization of the airway, breath-
ing, and circulation in a dyspnoeic patient, further 
etiological investigation including acute heart failure 
(AHF), pneumonia, and exacerbation of chronic ob-
structive pulmonary diseases (COPD) can proceed. 
Differential diagnosis should be prompt while pro-
viding appropriate first-line treatment for possibly 
lethal conditions [1].
Early ruling out of patients with COPD exacer-
bation from AHF for emergent medical intervention 
can be essential for emergency physicians in the 
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ED. As limited diagnostic information is available to 
emergency physicians for making decisions, there 
is a need for reliable diagnostic markers in patients 
with symptoms, mainly dyspnoea, suggestive of 
a cardiopulmonary pathology. There are several 
studies emphasizing the importance of haematolog-
ical biomarkers for differential diagnosis in patients 
with dyspnoea [2–4].
The neutrophil to lymphocyte ratio (NLR) is cal-
culated by dividing the number of neutrophils (NEU) 
by a number of lymphocytes (LYM) in a peripheral 
blood sample. The NLR is a simple parameter to 
assess the inflammatory status of a subject easily 
because it is relatively inexpensive and widely avail-
able as a part of a routine blood count analysis [5]. 
Furthermore, NLR has been demonstrated to be su-
perior to routine parameters like C-reactive protein 
(CRP) level, white blood cell (WBC) count and NEU 
count in predicting bacteraemia [6].
It is not always possible to immediately evalu-
ate every dyspnoeic patient with costly and com-
plex clinical assessments (echocardiography, nuclear 
scans, or cardiac catheterization) in the ED; besides, 
the prognostic benefit of these remains uncertain. 
Therefore, the authors sought to measure the ad-
ditive prognostic value provided by haematological 
parameters including NLR and PLR in patients with 
dyspnoea. The objective of this study determined 
whether NLR optimizes the differential diagnosis of 
acute chronic obstructive pulmonary disease (COPD) 
exacerbation and acute heart failure (AHF) utilizing 
clinical examination and laboratory parameters as 
main diagnostic tools in dyspnoeic patients admit-
ting to the ED of a university hospital.
MATERIALS AND METHODS
This was a retrospective cross-sectional study per-
formed on patients admitted to ED of a univer-
sity hospital with complaints of dyspnoea due to 
COPD exacerbation or systolic AHF between January 
2016 November 2018. After an initial evaluation, 
all patients were managed either in Department of 
Pulmonary Disease or Department of Cardiology. 
Patients with pulmonary embolism, acute myocar-
dial infarction, AHF unstable angina, history of AHF 
and COPD, pneumonia, AHF and infection, history 
of renal failure, lung cancer, more than 5 packet/ 
year smoker history, pregnancy, asthma and rhinitis, 
or those with missing complete blood count (CBC) 
values, were excluded from the study (Fig. 1).
Acute exacerbation of COPD was defined as an 
event in the natural course of the disease character-
ized by a change in the patient’s baseline respira-
tory symptoms such as dyspnoea, cough, sputum 
production, volume and colour change, that may 
warrant a change in regular medication in a patient 
with underlying COPD [7]. Acute heart failure is 
defined more broadly as a new onset or gradual or 
rapidly worsening HF [8]. 
COPD excorparaiton
Acute heart failure
Groups
Included
COPD exacerbation (n = 139) Acute heart failure (n = 102)
Patients presented with dyspnea and admitted to hospital with a diagnosis of
COPD exacerbation or acute heart failure (n = 241)
1135 patients additted to emergency service because of dyspnea in 2016–2018
Excluded
History of renal failure
Lung cancer
Astma and rhiniris
Pregnancy
History of AHF and
COPD
AHF and infection
Pulmonary embolism
Acute myocardial
infarction
Unstable angina
Pneumonia
> 5 packet/ years smoker
history
fIgURE 1. Schematic presentation of patient enrolment to the acute chronic obstructive pulmonary disease exacerbation and acute heart 
failure groups
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Following approval from the local ethics commit-
tee (2018-12/10), data were collected retrospectively 
from the hospital database. The recorded data were 
as follows: haemoglobin, leukocytes, neutrophils, 
lymphocytes, haemoglobin, mean platelet volume, 
and platelet distribution width (Mindray BC6800, 
China). NLR was calculated by dividing the absolute 
neutrophil count by the absolute lymphocyte count. 
PLR was calculated by dividing the absolute platelet 
count by the absolute lymphocyte count. CRP level 
was calculated with the nephelometry technique 
(Beckman Coulter, California, USA). Albumin, alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), γ-glutamyl transferase (GGT), glucose, direct 
bilirubin, total bilirubin, blood urea nitrogen (BUN), 
serum creatinine, sodium, potassium, creatine ki-
nase (CK), CK-MB, troponin levels were determined 
with the enzymatic colorimetric method (Mindray 
BS2000, USA). Blood gas analysis was performed 
(Radiometer ABL850 USA). Same methodology and 
devices were used for all the laboratory parameters 
during the search period. 
STATISTICAL ANALYSIS
IBM SPSS Statistics for Windows version 23.0 (IBM, 
Armonk, NY, USA) was used for statistical analy-
sis. Kolmogorov–Smirnov test was used as a test 
for normality for continuous data, and the results 
were expressed as median with 25th and 75th 
percentiles. Non-parametric Mann–Whitney U test 
was used to compare the means between two 
groups. Receiver operating characteristic (ROC) anal-
ysis was used to determine the diagnostic efficiency 
of NLR, CRP, WBC, and PLR, and the areas under the 
curve (AUCs) were compared. P < 0.05 was consid-
ered statistically significant.
RESULTS
There was no significant difference between the pa-
tients with acute COPD exacerbation and AHF regard-
ing mean age (70.5 + 13.7 and 71.7 + 11.3 years 
respectively) and female to male ratio (0.43 and 
0.56, respectively) (p > 0.05). Table 1 and Figure 2 
present CBC and biochemistry test results. The white 
blood cell (WBC), neutrophil, haematocrit, and 
NLR values in patients with acute COPD exacerba-
tion were significantly higher than in the patients 
with AHF (p < 0.05). The eosinophil and MCV val-
ue in patients with acute COPD exacerbation were 
significantly lower than that in patients with AHF 
(p < 0.05). The haemoglobin, lymphocyte, mono-
cyte, basophil, haemoglobin, PLR, and platelet values 
of the study groups were comparable (p > 0.05). 
GGT, direct bilirubin, total bilirubin, serum creatinine, 
CK, and troponin levels in patients with COPD exacer-
bation were significantly lower than in patients with 
AHF (p < 0.05). The CRP level in patients with COPD 
exacerbation was significantly higher than in patients 
with AHF (p < 0.05). AST, ALT, glucose, albumin, 
sodium, potassium, and CK-MB levels of the study 
groups were comparable (p > 0.05). Table 2 presents 
the blood gas parameters in acute COPD exacer-
bation and AHF. pCO2, COHb, and HCO3 values in 
patients with COPD exacerbation were significantly 
higher than in patients with AHF (p < 0.05). The pH, 
O2Hb, sO2 and pO2 values of the study groups were 
comparable (p > 0.05).
In addition, receiver operating characteristic curve 
(ROC) analyses with area under the curve (AUC) com-
parisons were used for determining the optimum 
cut-off value for CRP, NLR, WBC in predicting acute 
COPD exacerbation in patients with dyspnoea (Fig. 3). 
Among these inflammatory parameters, NLR had 
significance with the largest AUCs (p < 0.05). The 
cut-off value for NLR was 9.39, with a sensitivity of 
71.7% and a specificity of 61.1% and areas under 
the ROC curve: 0.716. The cut-off value for CRP was 
25.7, with a sensitivity of 58.6% and a specificity of 
57.6%, and areas under the ROC curve: 0.593. ROC 
analysis for WBC is comparable (p > 0.05).
DISCUSSION
In this study including 139 patients with acute COPD 
exacerbation and 102 patients with AHF hospital-
ized for management after the initial evaluation, the 
authors investigated the value of NLR as a diagnostic 
parameter for differential diagnosis in the ED. The 
age and sex ratio of study groups were comparable, 
and the inflammatory parameters including neutro-
phil values and CRP level increased in patients with 
acute COPD exacerbation. These findings enhance 
the clinical importance of higher NLR in patients 
with acute COPD exacerbation as a diagnostic pa-
rameter to differentiate these patients from patients 
with AHF. Other clinical parameters were supportive 
of the clinical nature of acute COPD exacerbation 
and AHF diseases. NLR can predict the patients with 
acute COPD exacerbation with a sensitivity and spec-
ificity of 71% and 61%, respectively. CRP level sen-
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sitivity and specificity (58% and 57%, respectively). 
Overall, NLR as an inflammatory parameter, especial-
ly in emergency room settings with basic laboratory 
conditions, has merit to be used for easy and rapid 
differential diagnosis between patients with acute 
COPD exacerbation and AHF. Besides, its clinical im-
plementation can decrease prolonged stays in the 
ED, reduce unnecessary hospitalizations, inappropri-
ate discharges, thus leading to better patient care. 
Dyspnoea is a common chief complaint as an 
uncomfortable subjective breathing sensation that 
is distressful or unpleasant in nature among ED 
patients [9]. Emergency clinicians need to establish 
the most likely causes of dyspnoea and initiate treat-
ment in such a patient. İn clinical practice, COPD is 
a frequent disease characterized by persistent res-
piratory symptoms including dyspnoea [10]. Patients 
with COPD are easily affected by many conditions 
that can lead to acute deterioration of the under-
lying COPD. Although COPD exacerbations are very 
Table 1. Baseline characteristics of COPD exacerbation and acute heart failure
COPD exacerbation 
(N = 139)
Acute Heart Failure
(N = 102) p
CBC, median (IQR) values
 WBC
 Neutrophil count
 Lymphocyte count
 Monocyte count
 Eosinophil count
 Basophilic count
 Haemoglobin, g/dL
 Haematocrit, %
 MCV, fL 
 Platelet count, 109
 NLR
 PLR
11.2 (8.2–14.4)
9.5 (6.7–13.3)
1 (0.57–1.37)
0.49 (0.25–0.76)
0.02 (0.01–0.08)
0.03 (0.02–0.05)
13.8 (12.2–15.5)
43.9 (39–50.3)
87.1 (80.3–91.5)
229 (170–292)
12.6 (8.4–22.9)
230 (146–392)
9.8 (7.9–12.4) 
7.7 (5.8–10.7)
1.02 (0.67–1.74)
0.56 (0.41–0.74)
0.07 (0.02–0.12)
0.03 (0.02–0.05)
12.8 (11.5–14.9)
41.2 (36.3–47.3)
88.9 (83.6–92.7)
228 (181–290)
8.1 (4.5–13.6)
224 (126–342)
0.068
0.003
0.276
0.107
0.041
0.806
0.054
0.008
0.037
0.418
< 0.001
0.065
Biochemistry
 Glucose, mg/dL
 Albumin, g/dL 
 ALT, U/L
 AST, U/L
 GGT, U/L
 Direct bilirubin, mg/dL
 Total bilirubin, mg/dL
 BUN, mg/dL
 Serum creatinine, mg/dL
 Sodium, mmol/L
 Potassium, mmol/L
 CK
 CKMB
 Troponin
 CRP, mg/dL
132 (115–156)
4.05 (3.8–4.2)
17 (9–27)
23 (18–32)
34 (22–61)
0.23(0.15–0.43)
0.63 (0.40–0.99)
23.6 (17.1–34.3)
0.95 (0.73–1.28)
136 (133–139)
4.3 (3.9–4.7)
58 (41–99)
32 (21–42)
0.03 (0.02–0.05)
42.4 (13.1–88.6)
131 (102–381)
3.81 (3.17–4.04)
18 (12–36)
28 (21–44)
56 (27–105)
0.28 (0.19–0.54)
0.78 (0.50–1.09)
28.2 (19.8–40.2)
1.13 (0.87–1.63)
135 (133–139)
4.2 (3.8–4.6)
77 (49–171)
32 (24–44)
0.05 (0.03–0.09)
22.1 (14.5–44.8)
0.767
0.370
0.075
0.193
< 0.001
0.003
0.006
0.013
0.031
0.95
0.241
0.005
0.636
0.021
< 0.001
CBC — complete blood count; WBC — white blood cell; MCV — mean corpuscular volume; NLR — Neutrophil to lymphocyte ratio; PLR — Platelet to lymphocyte ratio; ALT — ala-
nine aminotransferase; AST — aspartate aminotransferase; GGT — Gamma-glutamyl transferase; BUN — blood urea nitrogen; CK — creatine kinase; CKMB — creatine kinase-MB; 
CRP — C-reactive protein 
Data were expressed as median (25%–75% interquartile range) and were analysed with Mann–Whitney U test
N
LR
CR
P
W
BC
COPD exacerbation
COPD exacerbation
COPD exacerbation AHF
AHF
AHF
200
180
160
140
120
100
80
400
360
320
280
240
200
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120
80
70
60
50
40
30
20
10
0
50
40
30
20
16
12
8
4
0
40
30
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0
a
b
c
fIgURE 2. Neutrophil to lymphocyte ratio (NLR), white blood 
cell (WBC), and C-reactive protein (CRP) inflammatory markers in 
chronic obstructive pulmonary disease (COPD) exacerbation acute 
heart failure (AHF). a,b,P < 0.05, cP > 0.05 vs AHF
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common (about 20% of patients) and important, 
they are usually overlooked. Rapid and proper rec-
ognition of these patients along with appropriate 
treatment may be the only action that prevents 
respiratory failure and mortality [11–13]. Currently, 
there is no consensus for the assessment of the se-
verity and progression of acute COPD exacerbations 
by using a clinical tool [5].
Heart failure is also a critical clinical condition 
with findings such as dyspnoea, orthopnoea, lower 
limb swelling, and pulmonary congestion because of 
possible structural and/or functional cardiac abnor-
mality with important physiological abnormalities 
including reduced cardiac output and/or elevated 
intracardiac pressures [14]. Dyspnoea is the essential 
manifestation of HF and remains its most perplexing 
feature. 
COPD and HF are global epidemics, each affect-
ing more than 10 million patients [15]. In addition, 
both diseases often have common symptoms, and 
there is often significant overlap in the findings [16]. 
In order to prevent delays in treatment, objective 
and adequate diagnostic methods are needed in 
patients with unusual clinical manifestations and 
coinciding pathologies. Clinical, laboratory and ra-
diographic findings that contradict the clinician’s 
initial impressions must be carefully considered, as 
misdiagnosis may be associated with increased mor-
bidity and mortality. 
Kelly et al. [17] assessed the demographics and 
clinical presentation, assessment, treatment, and 
outcome of patients with acute COPD exacerbation 
managed in the EDs of Australasia and South East 
Asia. They included forty-six EDs to their research 
and found 415 eligible patients (13.6% of the over-
all cohort) with a primary diagnosis of acute COPD 
exacerbation (91% of them with previous COPD 
diagnosis) in the ED. The authors noted that those 
patients commonly required inpatient management 
and their in-hospital mortality was pronounced. 
They highlighted the suboptimal compliance of 
those patients to their suggested management pro-
tocols.
Laribi et al. [18] evaluated the epidemiology and 
management of dyspnoeic patients presenting to 
EDs in an international patient population in Europe 
and the Asia-Pacific region. Among 5569 patients, 
the most common ED diagnoses were lower respira-
tory tract infection (24.9%), heart failure (17.3%), 
COPD exacerbation (15.8%), and asthma (10.5%). 
Table 2. Comparison of blood gas parameters in COPD exacerbation and acute heart failure 
COPD exacerbation (N = 165) Acute Heart Failure(N = 115) P Value
pH
pCO2
pO2
COHb
HCO3
O2Hb
sO2
7.42 (7.36–7.45)
45 (34–58)
54.1 (44.7–67)
2.2 (1.8–2.8)
26 (22–31)
82 (74–88)
84 (75–90)
7.41 (7.36–7.46)
35.1 (31.3–45.1)
59.9 (51.3–70.1)
2 (1.7–2.5)
22.5 (19.2–25.3)
86 (79–90)
87 (81–93)
0.407
< 0.001
0.673
0.001
< 0.001
0.103
0.138
PCO2 — partial pressure of carbon dioxide; PO2 — partial pressure of oxygen; COHb — carboxyhaemoglobin; HCO3 — bicarbonate concentration; O2Hb — oxygenated haemoglobin; 
SO2 — oxygen saturation of haemoglobin 
Data were expressed as median (25%–75% interquartile range) and were analysed with Mann–Whitney U test
Se
ns
it
iv
it
y
ROC Curve
1 — Speciﬁcity
Source of the Curve
         NLR
         CRP
         WBC
         Reference Line
1,0
0,8
0,6
0,4
0,2
0,0
0,0                0,2                 0,4                 0,6                 0,8                 1,0
fIgURE 3. ROC curves of inflammatory markers for acute COPD 
exacerbation patients to AHF. Abbreviations: ROC, receiver  
operating characteristic; CRP, C-reactive protein; WBC, white blood 
cell NLR; neutrophil to lymphocyte ratio. ROC analysis for NLR  
(P < 0.001, areas under the ROC curve: 0.716; sensitivity: 71.7% 
and specificity: 61% for a cut-off of 9.39). ROC analysis for CRP 
(P = 0.021, areas under the ROC curve: 0.593; sensitivity: 58.6% 
and specificity: 57.6% for a cut-off of 25.7). ROC analysis for 
WBC (P = 0.092)
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They found that the overall in-hospital mortality was 
5.0%, especially 7.6% for heart failure and 5.6% for 
COPD patients. They suggested that exacerbations 
of chronic diseases including HF and COPD account 
for a large proportion of dyspnoeic patients in their 
population. They noted that dyspnoea at the ED was 
associated with a high rate of ward admission as 
well as suboptimal short-term outcomes. Similarly, 
all the patients in this study population were admit-
ted for inpatient management.
Patients with a COPD exacerbation may pres-
ent with dyspnoea and signs of right ventricular 
volume overload due to worsening cor pulmonale. 
In the management of these patients, laboratory 
testing should be performed in the context of the 
history and examination findings. Testing without 
a clear differential diagnosis can mislead the clini-
cian and delay appropriate management. The use 
of dyspnoea biomarker panels does not appear to 
improve accuracy beyond clinical assessment and 
focused testing [19]. Nevertheless, a plain chest ra-
diograph and an electrocardiogram are obtained 
in most ED patients with dyspnoea. Biomarkers are 
objective indications of the medical state of the pa-
tient. Natriuretic peptides, brain natriuretic peptide 
(BNP) and N-terminal prohormone of brain natriu-
retic peptide (NT-proBNP), have been accepted as 
the gold standard in assessing patients with heart 
failure. However, different cut-off values accepted 
for acute and chronic manifestations of heart failure 
are the main limitation of these biomarkers. Emer-
gency evaluation of patients with AHF in the ED may 
be suboptimal because of high-flow of patients, 
prolonged waiting time, and a deficit of medical 
staff [20]. In these patients, BNP levels are likely 
to be high, though usually not as high as cardiac 
dyspnoea [21]. The authors believe that simple and 
inexpensive laboratory tests like the NLR have po-
tential for widespread use in every level of EDs since 
other biomarkers still require further research for 
their optimization in patients with dyspnoea related 
to different types of aetiologies.
NLR has been used in patients with acute COPD 
exacerbation in several studies, mostly as an indi-
cator of exacerbation. Teng et al. [5] examined the 
predictive value of NLR in patients with acute COPD 
exacerbation. Their findings showed that NLR was 
higher in patients during admission and decreased 
after treatment according to clinical improvement. 
They suggested that NLR could be obtained quickly 
without any important burden to the patients and 
emergency clinicians, as it is convenient and relative-
ly inexpensive blood routine test. They concluded 
that NLR could also improve diagnostic accuracy 
when evaluating the severity and prognosis of acute 
COPD exacerbation with strong support for formu-
lating a treatment protocol in an emergency setting. 
They highlighted the importance of potential use of 
NLR as an easy test in community hospitals. Taylan 
et al. [22] assessed the place of NLR in patients with 
COPD for identifying recognition of acute exacerba-
tions. They found that NLR and other inflammatory 
markers, such as WBC, CRP, and ESR were found 
to be higher in COPD exacerbation compared to 
stable COPD. They noted that NLR could be used as 
a marker similar to the other inflammatory markers 
including CRP, WBC, and ESR in patients with acute 
COPD exacerbation. The findings of the current 
study support those data obtained from pertinent 
literature and the NLR can be considered as a tool 
for differential diagnosis of acute COPD exacerba-
tion in dyspnoeic patients admitted to ED.
In summary, within the initial laboratory workup, 
NLR as a simple laboratory parameter can be ad-
vantageous for emergency clinicians for the dif-
ferential diagnosis of acute exacerbation of COPD 
from AHF in patients presented to the ED with 
dyspnoea. This may be important for emergency 
physicians in hospitals without advanced laboratory 
test opportunities.
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